IKNA vs. FDMT, BNTC, LFVN, ITOS, DSGN, ACIU, ELDN, MNPR, AQST, and URGN
Should you be buying Ikena Oncology stock or one of its competitors? The main competitors of Ikena Oncology include 4D Molecular Therapeutics (FDMT), Benitec Biopharma (BNTC), LifeVantage (LFVN), iTeos Therapeutics (ITOS), Design Therapeutics (DSGN), AC Immune (ACIU), Eledon Pharmaceuticals (ELDN), Monopar Therapeutics (MNPR), Aquestive Therapeutics (AQST), and UroGen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry.
Ikena Oncology vs.
4D Molecular Therapeutics (NASDAQ:FDMT) and Ikena Oncology (NASDAQ:IKNA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
In the previous week, 4D Molecular Therapeutics had 10 more articles in the media than Ikena Oncology. MarketBeat recorded 13 mentions for 4D Molecular Therapeutics and 3 mentions for Ikena Oncology. Ikena Oncology's average media sentiment score of 0.50 beat 4D Molecular Therapeutics' score of 0.03 indicating that Ikena Oncology is being referred to more favorably in the news media.
99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. Comparatively, 75.0% of Ikena Oncology shares are owned by institutional investors. 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Comparatively, 5.9% of Ikena Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
4D Molecular Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Comparatively, Ikena Oncology has a beta of 0.48, suggesting that its stock price is 52% less volatile than the S&P 500.
4D Molecular Therapeutics presently has a consensus target price of $32.13, indicating a potential upside of 606.04%. Ikena Oncology has a consensus target price of $3.00, indicating a potential upside of 105.48%. Given 4D Molecular Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe 4D Molecular Therapeutics is more favorable than Ikena Oncology.
4D Molecular Therapeutics received 22 more outperform votes than Ikena Oncology when rated by MarketBeat users. Likewise, 67.53% of users gave 4D Molecular Therapeutics an outperform vote while only 58.82% of users gave Ikena Oncology an outperform vote.
4D Molecular Therapeutics' return on equity of -28.00% beat Ikena Oncology's return on equity.
Ikena Oncology has lower revenue, but higher earnings than 4D Molecular Therapeutics. 4D Molecular Therapeutics is trading at a lower price-to-earnings ratio than Ikena Oncology, indicating that it is currently the more affordable of the two stocks.
Summary
4D Molecular Therapeutics beats Ikena Oncology on 13 of the 17 factors compared between the two stocks.
Get Ikena Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for IKNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Ikena Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:IKNA) was last updated on 2/13/2025 by MarketBeat.com Staff